← Back to Search

Monoclonal Antibodies

23ME-01473 for Advanced Solid Cancers

Phase 1 & 2
Waitlist Available
Research Sponsored by 23andMe, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline until disease progression (up to 5 years)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called 23ME-01473 in patients with advanced solid cancers who have not responded well to standard treatments. The study aims to assess the safety, how well the

Who is the study for?
This trial is for adults over 18 with advanced solid cancers that have worsened after standard treatments. They should be relatively active (good performance status) and expected to live at least 12 more weeks. It's open to various cancer types as long as the disease can be evaluated.
What is being tested?
The study is testing a new drug, 23ME-01473, given through an IV. It aims to see how safe it is, how the body handles it, and if it works against different advanced solid tumors in patients who've run out of treatment options.
What are the potential side effects?
Since this is a first-in-human study for the drug 23ME-01473, specific side effects are not yet known but may include typical reactions related to IV infusions such as pain or swelling at the injection site, fever, chills or allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline until disease progression (up to 5 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline until disease progression (up to 5 years) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Disease Control Rate (DCR)
Duration of response (DoR)
Phase 1: Objective response rate (ORR)
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Phase 1Experimental Treatment1 Intervention
Participants will receive escalating doses of 23ME-01473

Find a Location

Who is running the clinical trial?

23andMe, Inc.Lead Sponsor
9 Previous Clinical Trials
83,849 Total Patients Enrolled
Jennifer Low, M.D,Ph.DStudy Director23andMe, Inc.
~3 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top